![]() Our center has a low prevalence of RBC alloimmunization among CLD patients. There was no significant factor association of RBC alloimmunization among CLD patients identified. The most common alloantibody identified belonged to the Rh blood group, anti-E (35.7%) and anti-c (14.3%), followed by the MNS blood group, anti-Mi a (17.9%). Most patients developed a single alloantibody (83.3%). Higher rates of alloimmunization were seen in females (7.1%) and patients with autoimmune hepatitis (11.1%). Twenty-four patients were reported to have RBC alloimmunization, resulting in an overall prevalence of 5.4%. ![]() The most common causes of CLD in our center are viral hepatitis (62.1%) and metabolic liver disease (25.4%). A total of 441 CLD patients were included in our study, with the majority being elderly, with the mean age of patients 57.9 (SD ± 12.1) years old, male (65.1%) and Malays (92.1%). Clinical and laboratory data were retrieved and statistically analyzed. This is a case-control study involving 441 patients with CLD who were being treated at Hospital Universiti Sains Malaysia and subjected to pre-transfusion testing from April 2012 until April 2022. We aimed to determine the prevalence of RBC alloimmunization and associated factors among chronic liver disease (CLD) patients in our center. Variations in the frequency of alloimmunization have been noted among different patient populations. Red blood cell (RBC) alloimmunization is an important complication of blood transfusion.
0 Comments
Leave a Reply. |